Independent Analysis Examines ColonBroom GLP-1 Booster Ingredient Transparency, Non-Prescription Supplement Category Context, and Company-Reported Formulation Details as Consumer Research Into ...

New global initiative urges patients and clinicians to wait for biomarker testing results before starting treatment.

A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibroste ...

Dr. Bethany Malone has treated a lot of colorectal cancer patients. The youngest, not counting those with genetic conditions, ...